EGFR and non-small cell lung carcinoma: EGFRL858R/T790M/C797S represents a triple mutation combination that is a major cause of acquired resistance to Osimertinib, the current third-generation EGFR tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) patients harboring the T790M mutation.